Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium. 

Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

“We looked at OS, PFS, and all the other efficacy end points, and it was clear that the benefit that we saw during the primary analysis in 2023 [with mirvetuximab soravtansine over chemotherapy] is still maintained [after long-term follow-up].”

Toon Van Gorp, MD, PhD, a gynecologic oncologist at Universitair Ziekenhuis Leuven in Belgium, discusses final data from the phase 3 MIRASOL trial (NCT04209855) evaluating mirvetuximab soravtansine-gynx (Elahere) in patients with folate receptor alpha (FRα)–positive platinum-resistant ovarian cancer.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gynecologic Oncology

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

SGO Annual Meeting

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.